<DOC>
	<DOCNO>NCT00049712</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient refractory advanced solid tumor lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Refractory Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) monoclonal antibody anti-alpha V beta 3 integrin ( MEDI 522 ) patient refractory advanced solid tumor lymphoma . - Determine safety tolerability drug patient . - Demonstrate significant binding drug molecular target vivo patient . - Determine effect drug angiogenesis patient . - Determine antitumor activity drug measure tumor size glucose uptake patient . - Determine pharmacokinetics drug patient . - Determine recommend phase II dose drug base either MTD optimal biologic response patient . OUTLINE : This dose-escalation study . Patients receive monoclonal antibody anti-alpha V beta 3 integrin ( Medi 522 ) IV 30 minute weekly . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos Medi 522 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 6-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor lymphoma refractory currently available standard therapy curative therapy No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 12 week Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No prior bleed disorder Hepatic Bilirubin normal AST/ALT great 2.5 time upper limit normal INR/PTT normal Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation HIV negative T4 thyroid stimulate hormone normal No thyroid disease No prior allergic reaction attribute compound similar chemical biologic composition study drug ( e.g. , rituximab immunoglobulin G ) No ongoing active infection No uncontrolled concurrent illness would preclude study participation No psychiatric illness social situation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery More 4 week since prior surgery Other No concurrent investigational agent No concurrent anticancer agent therapy ( commercial investigational )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>